12:00 AM
 | 
Aug 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AMR-001: Phase II ongoing

NeoStem's Amorcyte LLC subsidiary said a DSMB recommended continuation of the double-blind, placebo-controlled, U.S. Phase II PreSERVE AMI trial of AMR-001 based on interim...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >